Cargando…
Influencing factors of efficacy and long‐term use of amrubicin in patients with small cell lung cancer
BACKGROUND: Amrubicin (AMR) has become the standard of care for post‐relapse small cell lung cancer (SCLC). It has also been reported to achieve long‐term disease control in patients with good treatment response. However, the optimal patient population for whom AMR is effective and the factors assoc...
Autores principales: | Takahara, Yutaka, Tanaka, Takuya, Ishige, Yoko, Shionoya, Ikuyo, Yamamura, Kouichi, Sakuma, Takashi, Nishiki, Kazuaki, Nakase, Keisuke, Nojiri, Masafumi, Kato, Ryo, Shinomiya, Shohei, Oikawa, Taku, Mizuno, Shiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175028/ https://www.ncbi.nlm.nih.gov/pubmed/36994539 http://dx.doi.org/10.1111/1759-7714.14871 |
Ejemplares similares
-
Differential response in patients with large cell neuroendocrine carcinoma of the lung to initial therapy: A case series
por: Takahara, Yutaka, et al.
Publicado: (2022) -
Early recurrence factors in patients with stage III non‐small cell lung cancer treated with concurrent chemoradiotherapy
por: Takahara, Yutaka, et al.
Publicado: (2022) -
Risk factors for acute exacerbation in lung cancer complicated by interstitial lung disease with slight reticular shadows
por: Takahara, Yutaka, et al.
Publicado: (2021) -
Efficacy and predictors of rechallenge with immune checkpoint inhibitors in non‐small cell lung cancer
por: Takahara, Yutaka, et al.
Publicado: (2022) -
Investigation of response factors for monotherapy with immune checkpoint inhibitors in non‐small cell lung cancer patients with PD‐L1 expression <50%
por: Takahara, Yutaka, et al.
Publicado: (2023)